Catalent ($CTLT) has partnered with the Lung Cancer Alliance to survey patients on how they manage the disease and deal with treatment compliance, an effort to highlight unmet needs and match them with new dosage forms. The partnership centers on the Catalent Applied Drug Delivery Institute, an internal effort to develop new approaches for getting medications to patients safely and effectively. Alongside the Lung Cancer Alliance, Catalent hopes to cull patient insights about barriers to adherence, information that could fuel future R&D. More